Quarterly ResultMay 12, 2026, 08:22 AM
NeuroOne Q2 Net Loss $(3.52M); Cash Down 57%; Going Concern Doubt
AI Summary
NeuroOne Medical Technologies reported a net loss of $(3.52) million for the six months ended March 31, 2026, a significant increase from $(0.49) million in the prior year, despite product revenue growing 13.4% to $5.28 million. Cash and cash equivalents sharply declined by 57% to $2.80 million, leading management to express substantial doubt about the company's ability to continue as a going concern, with current funds projected to last only through September 2026. The company also completed a 1-for-6 reverse stock split in April 2026.
Key Highlights
- Net loss for the six months ended March 31, 2026, widened to $(3,523,559) from $(485,285) in the prior year.
- Cash and cash equivalents decreased 57.3% to $2,804,011 as of March 31, 2026, from $6,570,382 at September 30, 2025.
- Management expressed substantial doubt about the company's ability to continue as a going concern, with cash projected to last only through September 2026.
- Product revenue for the six months ended March 31, 2026, increased 13.4% to $5,283,820 from $4,660,717 in the prior year.
- Net cash used in operating activities was $(4,444,546) for the six months ended March 31, 2026, compared to $151,905 provided in the prior year.
- The company reported an accumulated deficit of $82.1 million as of March 31, 2026.
- A 1-for-6 reverse stock split was effectuated on April 14, 2026, with trading on a split-adjusted basis commencing April 16, 2026.
- The limited market release of the OneRF TN Ablation System was completed in March 2026.